clotrimazole has been researched along with HbS Disease in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have examined the effect of hydroxyurea (HU), clotrimazole (CLT), magnesium oxide (Mg), and combined CLT+Mg therapies on the erythrocyte characteristics and their response to chronic hypoxia in a transgenic sickle mouse (SAD) model." | 7.70 | Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. ( Beuzard, Y; Brugnara, C; De Franceschi, L; Jouault, H; Rouyer-Fessard, P, 1999) |
| "We have examined the effect of hydroxyurea (HU), clotrimazole (CLT), magnesium oxide (Mg), and combined CLT+Mg therapies on the erythrocyte characteristics and their response to chronic hypoxia in a transgenic sickle mouse (SAD) model." | 3.70 | Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. ( Beuzard, Y; Brugnara, C; De Franceschi, L; Jouault, H; Rouyer-Fessard, P, 1999) |
| "A prominent feature of sickle cell anemia is the presence of dehydrated red blood cells (RBCs) in circulation." | 1.32 | ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. ( Beuzard, Y; Brugnara, C; Corrocher, R; De Franceschi, L; McNaughton-Smith, GA; Stocker, JW, 2003) |
| "Clotrimazole (CLT) has recently been shown to be a potent and specific inhibitor of the Ca(2+)-activated K+ channel and to thereby prevent K+ loss and cellular dehydration of sickled erythrocytes." | 1.29 | HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. ( Armsby, CC; Brugnara, C; Law, T; Mikati, M; Platt, O; Rifai, N; Sakamoto, M, 1995) |
| "We treated five subjects who have sickle cell anemia with oral clotrimazole, a specific Gardos channel inhibitor." | 1.29 | Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. ( Alper, SL; Armsby, CC; Brugnara, C; Gee, B; Kurth, S; Platt, OS; Rifai, N; Sakamoto, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (64.71) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McNaughton-Smith, GA | 2 |
| Burns, JF | 1 |
| Stocker, JW | 2 |
| Rigdon, GC | 1 |
| Creech, C | 1 |
| Arrington, S | 1 |
| Shelton, T | 1 |
| de Franceschi, L | 6 |
| Gbotosho, OT | 1 |
| Cytlak, UM | 1 |
| Hannemann, A | 1 |
| Rees, DC | 1 |
| Tewari, S | 1 |
| Gibson, JS | 1 |
| Corrocher, R | 1 |
| Beuzard, Y | 4 |
| Brugnara, C | 8 |
| Perry, V | 1 |
| Saadane, N | 2 |
| Trudel, M | 2 |
| Alper, SL | 4 |
| Armsby, CC | 3 |
| Rittenhouse, A | 1 |
| Rifai, N | 3 |
| Platt, O | 2 |
| Sakamoto, M | 2 |
| Law, T | 1 |
| Mikati, M | 1 |
| Stuart, J | 1 |
| Mojiminiyi, FB | 1 |
| Stone, PC | 1 |
| Culliford, SJ | 1 |
| Ellory, JC | 1 |
| Mohandas, N | 1 |
| Paszty, C | 1 |
| Gee, B | 1 |
| Kurth, S | 1 |
| Platt, OS | 1 |
| Charache, S | 1 |
| Shartava, A | 2 |
| Shah, AK | 2 |
| Goodman, SR | 2 |
| Rouyer-Fessard, P | 1 |
| Jouault, H | 1 |
| McIntyre, J | 1 |
| Lew, VL | 1 |
| Etzion, Z | 1 |
| Bookchin, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises With[NCT00102791] | Phase 3 | 297 participants (Actual) | Interventional | 2005-02-28 | Terminated (stopped due to Because of the low probability of achieving the primary endpoint.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for clotrimazole and HbS Disease
| Article | Year |
|---|---|
A new therapeutic approach for sickle cell disease. Blockade of the red cell Ca(2+)-activated K+ channel by clotrimazole.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Calcium; Clotrimazole; Disease Models, Animal; E | 1995 |
Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antifungal Agents; Clotrimazole; Erythrocytes; Humans; Ion Transport; Magnesium | 1995 |
Treatment of sickling disorders.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Component Removal; Blood Transfusi | 1996 |
14 other studies available for clotrimazole and HbS Disease
| Article | Year |
|---|---|
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Biological Availability; Clotrimazole; Humans; Intermediat | 2008 |
Inhibitors of second messenger pathways and Ca(2+)-induced exposure of phosphatidylserine in red blood cells of patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Calcium; Charybdotoxin; Clotrimazole; Enzyme Inhibitors; Erythrocytes; Humans; | 2014 |
ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Calcium; Calcium Channel Blockers; Clotrimazole; Erythrocy | 2003 |
Myths and facts...about sickle-cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Clotrimazole; Hemoglobin, Sickle; Humans; Hydroxyurea; Nit | 2005 |
Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Calcium; Clotrimazole; Erythrocytes; Female; Hem | 1994 |
HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent.
Topics: Adenosine Triphosphatases; Anemia, Sickle Cell; Biological Transport; Chromatography, High Pressure | 1995 |
Additive in vitro effects of anti-sickling drugs.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Calcium; Cells, Cultured; Clotrimazole; Dru | 1994 |
Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.
Topics: Anemia, Sickle Cell; Biological Transport; Calcium; Clotrimazole; Erythrocytes, Abnormal; Humans; Im | 1993 |
Sickle cell disease: a step closer to the dream.
Topics: Anemia, Sickle Cell; Clotrimazole; Humans; Potassium Channel Blockers | 1996 |
Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.
Topics: Administration, Oral; Anemia, Sickle Cell; Antisickling Agents; Clotrimazole; Erythrocytes; Humans; | 1996 |
N-acetylcysteine and clotrimazole inhibit sickle erythrocyte dehydration induced by 1-chloro-2,4-dinitrobenzene.
Topics: Acetylcysteine; Anemia, Sickle Cell; Carboxylic Acids; Carrier Proteins; Clotrimazole; Desiccation; | 1999 |
Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Chronic Disease; Clotrimazole; Drug Therapy, Com | 1999 |
The Gardos channel is responsible for CDNB-induced dense sickle cell formation.
Topics: Anemia, Sickle Cell; Clotrimazole; Dinitrochlorobenzene; Glutathione; Growth Inhibitors; Humans; Hyd | 2000 |
Dehydration response of sickle cells to sickling-induced Ca(++) permeabilization.
Topics: Anemia, Sickle Cell; Calcium; Cell Membrane Permeability; Clotrimazole; Desiccation; Erythrocyte Mem | 2002 |